View Clinical Trial (Medical Research Study)

Domperidone for Relief of Gastrointestinal Disorders - NCT00761254-61801(Clinical Trial 243502)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Urbana
State:  
IL
Zip Code: 61801
Conditions: Gastroparesis - GERD - Esophagitis - Dyspepsia - Chronic Constipation - Nausea and Vomiting
Purpose: The purpose of this study is to make Domperidone available to patients with gastrointestinal disorders who have failed standard therapy and who might benefit from it.
Study summary: Domperidone is the only medication that is a true prokinetic with a low percentage of side effects that is useful in the treatment of certain GI conditions, including gastroparesis and other motility disorders. According to recent regulations, writing prescriptions for subject to obtain domperidone outside the United States has been determined to be illegal and the FDA has issued warnings against pharmacies compounding domperidone. The legal way of administering domperidone is by obtaining an Investigational New Drug Application. This study is an effort to both follow federal regulations and provide the medication to subjects who would benefit from it where standard therapy has failed.
Criteria: Inclusion Criteria: - 18 years or older - symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms, gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that is refractory to standard therapy - subjects must have a comprehensive evaluation to eliminate other causes of their symptoms. Exclusion Criteria: - history of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation, and Torsade de pointes. Subjects with minor forms of ectopy (PACs) are not necessarily excluded. - clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged QTc (QTc > 450 milliseconds for males, QTc > 470 milliseconds for females.) - clinically significant electrolyte disorders. - gastrointestinal hemorrhage or obstruction. - presence of a prolactinoma (prolactin-releasing pituitary tumor.) - pregnant or breast feeding female. - known allergy to Domperidone.
Study is available at: Carle Health Care Incorporated d/b/a Carle Physician Group
Urbana, IL 61801
United States

Primary Contact:
Micki Suits, RN
Email: micki.suits@carle.com
Phone: 217-326-0058

Secondary Contact:
Micki J Suits, RN
Email: micki.suits@carle.com
Phone: 217-326-0058
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.